Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Details
- Category: Business
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals ages 12 years and older.
Novartis invests in early technical development capabilities for next-generation biotherapeutics
- Details
- Category: Novartis
Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will bolster its capacity and capabilities for early technical development of biologics. Spanning both drug substance and drug product development, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia and Austria,
FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.
Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
- Details
- Category: Sanofi
The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Xenpozyme is the first therapy indicated specifically for the treatment of ASMD, and is currently the only approved treatment for this disease.
BioNTech's statement on patent infringement lawsuit filed by Moderna
- Details
- Category: Business
BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® infringes certain Moderna patents. BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement.
Moderna sues Pfizer and BioNTech for infringing patents central to Modernas innovative mRNA technology platform
- Details
- Category: Business
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
- Details
- Category: Novartis
Novartis today announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.
The spin-off aims to maximize shareholder value by creating the #1 European generics company(1) and a global leader in biosimilars, allowing Novartis shareholders to participate fully in the potential future upside for both Sandoz and Novartis Innovative Medicines.
More Pharma News ...
- Pfizer and BioNTech submit application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
- Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage"
- Pfizer announces positive top-line results from Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants
- Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
- Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
- Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
- Bayer Consumer Health leaders propose new principles for science-led self-care